Clin2
NCT07323173Possibly a fitRecruiting

Safety study of LBL-047 in healthy adults and lupus patients

Systemic Lupus Erythematosus

Part of Immune system & allergy, Skin clinical trials.

This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
117 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • You must be between 18 and 60 years old.
  • You need to have either mild to moderate lupus or be a healthy volunteer (depending on the part of the study).
  • If you can become pregnant or get someone pregnant, you must agree to use effective birth control during the study and for 6 months after.
  • You must not have had an organ transplant or a stem cell transplant.
  • You must not have a chronic infection (like certain fungal, viral, or bacterial infections).
  • You must not have had major surgery within the last 90 days.
  • You must not have a large tattoo or scar at the injection site.
  • You must not have a fear of needles or blood that would make it hard to have blood drawn.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07109986Recruiting· Phase 1
Study of UB-VV410 for active lupus or lupus nephritis

This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.

Nanjing
NCT06576271Recruiting· Phase 1
Testing a new drug for lupus and related lung disease

This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.

Scottsdale, Arizona
NCT07299422Recruiting· Phase 2
Study of SHR-2173 for people with lupus

This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.

Beijing, Beijing Municipality
NCT07409181Recruiting· Phase 2
Testing an experimental pill for active lupus (SLE)

This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.

Beverly Hills, California
NCT06857214Recruiting· Phase 1
GNC-038 antibody study for moderate to severe lupus

This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.

Shanghai, Shanghai Municipality
NCT07371468Recruiting· Phase 1
Study of an experimental drug for lupus, rheumatoid arthritis, and related conditions

This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.

Buenos Aires

Hear when a new Systemic Lupus Erythematosus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.